Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 22411614)

1.

Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.

McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C, Rida W, Pym A, Smith PJ, Onyebujoh PC.

Antimicrob Agents Chemother. 2012 Jun;56(6):3232-8. doi: 10.1128/AAC.05526-11. Epub 2012 Mar 12.

2.

Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW.

Clin Infect Dis. 2009 Jun 15;48(12):1685-94. doi: 10.1086/599040.

3.

Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7. doi: 10.1128/AAC.05429-11. Epub 2011 Oct 3.

4.

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P.

Antimicrob Agents Chemother. 2006 Apr;50(4):1170-7.

5.

Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.

Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R.

Antimicrob Agents Chemother. 2010 Mar;54(3):1068-74. doi: 10.1128/AAC.00447-09. Epub 2009 Dec 28.

6.

Low antituberculosis drug concentrations in patients with AIDS.

Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, Berning SE, Gerena GT.

Ann Pharmacother. 1996 Sep;30(9):919-25.

PMID:
8876848
7.

Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.

Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Bhagavathy S, Venkatesan P, Sekar L, Mahilmaran A, Ravichandran N, Paramesh P.

Antimicrob Agents Chemother. 2004 Nov;48(11):4473-5.

8.

Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van Crevel R, Aarnoutse R.

Antimicrob Agents Chemother. 2013 Aug;57(8):3614-9. doi: 10.1128/AAC.02468-12. Epub 2013 May 20.

9.

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE.

Antimicrob Agents Chemother. 2007 Jul;51(7):2546-51. Epub 2007 Apr 23.

10.

Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.

Babalik A, Ulus IH, Bakirci N, Kuyucu T, Arpag H, Dagyildizi L, Capaner E.

Antimicrob Agents Chemother. 2013 Nov;57(11):5740-2. doi: 10.1128/AAC.01345-13. Epub 2013 Aug 26.

11.

Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.

Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ, Aarnoutse RE.

Antimicrob Agents Chemother. 2013 Jul;57(7):3208-13. doi: 10.1128/AAC.02599-12. Epub 2013 Apr 29.

12.

Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.

Verhagen LM, López D, Hermans PW, Warris A, de Groot R, García JF, de Waard JH, Aarnoutse RE.

Trop Med Int Health. 2012 Dec;17(12):1449-56. doi: 10.1111/tmi.12003. Epub 2012 Oct 24.

13.

The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis.

Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, Hafner R, Peloquin CA; AIDS Clinical Trials Group 309 Team.

Clin Infect Dis. 2005 Dec 1;41(11):1638-47. Epub 2005 Oct 28.

15.

Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T.

J Infect Dis. 2013 Nov 1;208(9):1464-73. doi: 10.1093/infdis/jit352. Epub 2013 Jul 29.

16.

Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.

Sahai J, Gallicano K, Swick L, Tailor S, Garber G, Seguin I, Oliveras L, Walker S, Rachlis A, Cameron DW.

Ann Intern Med. 1997 Aug 15;127(4):289-93.

PMID:
9265429
17.

Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.

Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J.

Antimicrob Agents Chemother. 2009 Oct;53(10):4178-84. doi: 10.1128/AAC.00830-09. Epub 2009 Jul 20.

18.

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.

Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D.

Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7. Epub 2003 Jan 31.

PMID:
12569078
19.

Does AIDS impair the absorption of antituberculosis agents?

Taylor B, Smith PJ.

Int J Tuberc Lung Dis. 1998 Aug;2(8):670-5.

PMID:
9712282
20.

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T; Tuberculosis Trials Consortium.

Clin Infect Dis. 2005 May 15;40(10):1481-91. Epub 2005 Apr 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk